ubtd1 Antibody

What is UBTD1 and why is it significant in research?

UBTD1 is a ubiquitin-like protein that regulates the ubiquitin-proteasome system (UPS)-mediated protein degradation and has been implicated in several cancer types. Research has shown that UBTD1 plays crucial roles in:

• Regulating ceramide balance and endolysosomal positioning

• Controlling cancer cell mechanical properties via RhoA activation

• Mediating YAP ubiquitylation through interaction with β-TrCP

• Promoting colorectal cancer progression via the β-TrCP/c-Myc/HK2 pathway and glycolysis enhancement

The complex functions of UBTD1 in cellular homeostasis and disease progression make it an important target for antibody-based research techniques.

What types of UBTD1 antibodies are available for research applications?

Based on current research literature and commercial offerings, UBTD1 antibodies are primarily available as:

• Polyclonal antibodies (such as rabbit-derived polyclonal antibodies)

• Non-conjugated antibodies for standard detection methods

• Antibodies optimized for specific applications including Western blot and ELISA

When selecting an antibody, researchers should consider species reactivity (with human UBTD1 being the most commonly targeted), clonality, and validated applications specific to their experimental design.

What is the recommended sample preparation for UBTD1 detection in different cell types?

For optimal UBTD1 detection in various cell types, researchers should follow these methodological approaches:

• For adherent cancer cell lines (e.g., DU145, A549):

  • Harvest cells at 70-80% confluence to ensure proper protein expression

  • Lyse cells in RIPA buffer containing protease inhibitor cocktail

  • Centrifuge lysates at 16,000 g for 10 minutes at 4°C to remove debris

• For subcellular fractionation (to study UBTD1's membrane localization):

  • Perform standard nuclear, cytosolic, and membrane extraction protocols

  • UBTD1 is highly enriched in the membrane fraction of confluent cells, particularly at cell-cell contacts

• For colorectal cancer tissue samples:

  • Use appropriate tissue preservation methods (fresh-frozen or FFPE)

  • For immunohistochemistry, process 2-μm-thick sections using standard protocols

How should researchers optimize Western blot protocols for UBTD1 detection?

For reliable Western blot detection of UBTD1, follow these methodological guidelines:

• Sample preparation:

  • Use 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS buffer with protease inhibitors

  • Load 20-40 μg of total protein per lane

• Gel electrophoresis and transfer:

  • Separate proteins on 10-12% SDS-PAGE gels

  • Transfer to PVDF membranes at 100V for 60-90 minutes

• Antibody incubation:

  • Block membranes with 5% non-fat milk in TBST

  • Use anti-UBTD1 antibody at recommended dilution (typically 1:1000)

  • Incubate overnight at 4°C with gentle rocking

  • Use appropriate HRP-conjugated secondary antibody

• Visualization:

  • Expected molecular weight of UBTD1 is approximately 33 kDa

  • Include appropriate loading controls (e.g., GAPDH, β-actin)

Research has demonstrated successful UBTD1 detection in various cell lines including DU145 (prostate cancer) and A549 (lung cancer) .

What are the validated co-immunoprecipitation methods for studying UBTD1 protein interactions?

UBTD1 has been shown to interact with several proteins including β-catenin and YAP. To study these interactions:

• Cell lysate preparation:

  • Harvest cells and lyse in RIPA buffer containing protease inhibitor cocktail

  • Clear lysates by centrifugation (16,000 g, 10 min, 4°C)

• Immunoprecipitation protocol:

  • Incubate lysates with anti-UBTD1 antibody for 2 hours at 4°C

  • Add 10 μl Dynabeads protein A and incubate for 45 minutes at 4°C

  • Wash beads 3-5 times with RIPA buffer

  • Elute by boiling in 2× sample buffer at 95°C for 10 minutes

• Analysis:

  • Analyze eluted fractions by Western blot using antibodies against potential interacting partners

  • Research has confirmed UBTD1 interactions with β-catenin and YAP using this methodology

How can researchers perform ubiquitylation assays to study UBTD1's role in protein degradation?

UBTD1 plays a critical role in regulating protein ubiquitylation. To study this function:

• Transfection setup:

  • Transfect cells (6×10^6) with 10 μg of His-tagged ubiquitin expression vectors

  • Co-transfect with constructs expressing proteins of interest (e.g., YAP)

  • Include siRNA targeting UBTD1 or control siRNA

• Ubiquitylated protein recovery:

  • Recover ubiquitylated proteins by His-tag affinity purification on cobalt resin under urea denaturing conditions

  • Wash thoroughly to remove non-specific binding

• Detection:

  • Analyze purified ubiquitylated proteins by Western blot using antibodies against the protein of interest

  • Research has demonstrated that UBTD1 depletion reduces ASAH1 ubiquitination, supporting its role in ASAH1 degradation

How can researchers address discrepancies in UBTD1 expression patterns across different cancer types?

Research has revealed contradictory roles for UBTD1 in different cancer types:

To address these discrepancies:

• Use tissue-specific controls and multiple antibody validation techniques

• Implement rigorous statistical analysis accounting for cancer subtypes and stages

• Conduct parallel studies using complementary techniques (IHC, Western blot, RT-PCR)

• Consider context-dependent functions of UBTD1 in different cellular environments

• Validate findings across multiple patient cohorts and experimental models

What are the recommended approaches for studying UBTD1's subcellular localization and its functional implications?

UBTD1 exhibits complex subcellular localization patterns that are functionally significant:

• Immunofluorescence methodology:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.1% Triton X-100

  • Block with 3% BSA

  • Use validated anti-UBTD1 antibody at appropriate dilution

  • Co-stain with markers for cell-cell contacts (E-cadherin, β-catenin)

• Key observations from research:

  • In confluent cells, UBTD1 localizes close to the cell membrane at cell-cell contact sites

  • UBTD1 is juxtaposed with E-cadherin but co-localizes with β-catenin

  • UBTD1's association with YAP occurs mainly in the cytoplasm

  • Cell density increases UBTD1 expression and affects its localization

• Functional implications:

  • UBTD1's membrane localization correlates with cell adhesion properties

  • Its cytoplasmic association with YAP regulates YAP degradation

  • Different subcellular pools of UBTD1 may perform distinct functions

What controls and validation techniques are essential when using UBTD1 antibodies in cancer research?

When conducting UBTD1 antibody-based cancer research, implement these validation approaches:

• Essential controls:

  • Positive control (cells/tissues known to express UBTD1)

  • Negative control (UBTD1 knockout or siRNA-depleted samples)

  • Isotype control antibody

  • Secondary antibody-only control

• Validation techniques:

  • Western blot to confirm antibody specificity at the expected molecular weight

  • siRNA knockdown to demonstrate specificity (using siUBTD1pool or single siRNAs)

  • Immunoprecipitation followed by mass spectrometry

  • Proximity ligation assay (PLA) to confirm protein-protein interactions

• Reproducibility considerations:

  • Use multiple antibody clones when possible

  • Validate findings across different cell lines and tissue types

  • Document all experimental conditions thoroughly

How should researchers interpret UBTD1's dual roles in cancer progression across different tumor types?

The paradoxical roles of UBTD1 in different cancer types require careful interpretation:

• In prostate and lung cancers:

  • UBTD1 appears to function as a tumor suppressor

  • IHC analysis shows complete disappearance of UBTD1 staining in cancerous cells

  • High UBTD1 expression correlates with better patient survival and slower disease progression

• In colorectal cancer:

  • UBTD1 functions as an oncogene

  • Expression is significantly higher in cancer tissue than adjacent normal tissue

  • Higher expression associates with poorer survival and increased lymph node metastasis

  • Promotes CRC progression through the β-TrCP/c-Myc/HK2 pathway

• Interpretation framework:

  • Consider tissue-specific molecular contexts and signaling pathways

  • Evaluate UBTD1's interaction partners in each cancer type

  • Analyze the metabolic and mechanical differences between cancer types

  • Assess the developmental origin of different cancer types (e.g., basal vs. luminal)

What methodological approaches can resolve contradictory findings in UBTD1 research?

To address contradictory findings about UBTD1's role in cancer:

• Comprehensive expression analysis:

  • Use RNA-seq, proteomics, and IHC in matched tumor/normal samples

  • Analyze UBTD1 expression across cancer stages and subtypes

  • Incorporate data from large patient cohorts (e.g., TCGA database)

• Mechanistic studies:

  • Investigate tissue-specific interaction partners and substrates

  • Examine post-translational modifications of UBTD1 in different contexts

  • Study the impact of microenvironment on UBTD1 function

• Functional validation:

  • Use both overexpression and knockdown approaches

  • Implement rescue experiments to confirm specificity

  • Utilize 3D organoid models that better recapitulate tumor biology

  • Apply CRISPR-Cas9 technology for complete gene knockout

• Statistical and bioinformatic approaches:

  • Conduct meta-analyses across multiple datasets

  • Use multivariate analysis to account for confounding factors

  • Implement machine learning to identify patterns in complex datasets

What experimental design is recommended for studying UBTD1's role in the mechanical properties of cancer cells?

Research has established UBTD1 as a mechano-regulator controlling cancer aggressiveness . To study this function:

• Cell mechanical property assessment:

  • Use atomic force microscopy (AFM) to measure cell elasticity

  • Compare UBTD1-depleted cells with control cells

  • Analyze changes in the elastic modulus as a measure of cell deformability

• Cytoskeletal dynamics analysis:

  • Perform RhoA-GTP pull-down assays to monitor RhoA activity

  • Study actomyosin contractility and cytoskeletal rearrangements

  • Use live-cell imaging to track cytoskeletal changes

• Cell adhesion measurements:

  • Analyze cell-cell and cell-matrix adhesion parameters

  • Study the relationship between cell density and UBTD1 expression

  • Investigate co-localization with adhesion complex components

• Migration and invasion assays:

  • Conduct wound healing assays for 2D migration

  • Use transwell chambers for invasion studies

  • Implement 3D human organoid technology to evaluate cancer cell invasion

Research has shown that UBTD1 depletion increases cell elastic modulus, activates RhoA, and enhances migratory and invasive properties of cancer cells .

What are the promising areas for developing enhanced UBTD1 antibodies for cancer research?

Based on current research gaps, development of the following UBTD1 antibodies would advance the field:

• Phospho-specific antibodies:

  • Target potential phosphorylation sites that may regulate UBTD1 function

  • Enable research into post-translational regulation mechanisms

• Isoform-specific antibodies:

  • Distinguish between potential UBTD1 isoforms in different tissues

  • Allow for more precise mapping of domain-specific functions

• Antibodies with enhanced application versatility:

  • Optimized for multiple applications beyond Western blot (ChIP, IHC, IF)

  • Compatible with different species for comparative studies

• High-sensitivity antibodies:

  • Capable of detecting low-abundance UBTD1 in clinical samples

  • Suitable for early diagnostic applications in cancer

How can researchers design experiments to elucidate UBTD1's role in metabolic reprogramming in cancer?

Recent findings suggest UBTD1 influences cancer metabolism . To investigate this function:

• Metabolic profiling:

  • Conduct metabolomics analysis comparing UBTD1-overexpressing and knockdown cells

  • Focus on glycolysis pathway metabolites, which have shown significant changes

  • Measure key metabolic parameters including:

    • Lactate production

    • Glucose uptake

    • ATP generation

    • Oxygen consumption rate

• Enzyme activity assays:

  • Focus on hexokinase II (HK2), identified as a downstream target

  • Measure activity of other glycolytic enzymes to map the metabolic pathway fully

• Signaling pathway analysis:

  • Investigate the β-TrCP/c-Myc/HK2 pathway identified in colorectal cancer

  • Study UBTD1's effect on c-Myc protein stability and half-life

  • Use cycloheximide chase assays to measure protein degradation rates

• Therapeutic implications:

  • Test whether glycolysis inhibitors show synergistic effects with UBTD1 modulation

  • Evaluate UBTD1 as a biomarker for predicting response to metabolic-targeting therapies